Health Care [ 9/12 ] | Pharmaceuticals [ 61/74 ]
NASDAQ | Common Stock
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc.
In addition, the company is also involved in the development of generic topical dermatological drug products.
It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.01 Increased by +95.24% | -0.05 Increased by +80.00% |
| Aug 16, 24 | 0.07 Increased by +131.82% | -0.20 Increased by +135.00% |
| May 20, 24 | -0.23 Increased by +43.90% | -0.15 Decreased by -53.33% |
| Mar 13, 24 | -0.17 Increased by +32.00% | -0.17 |
| Nov 9, 23 | -0.21 Decreased by -40.00% | -0.23 Increased by +8.70% |
| Aug 10, 23 | -0.22 Decreased by -2.10 K% | -0.25 Increased by +12.00% |
| May 12, 23 | -0.41 Decreased by -70.83% | -0.21 Decreased by -95.24% |
| Mar 10, 23 | -0.25 Decreased by -140.98% | -0.12 Decreased by -108.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 278.00 K Decreased by -40.34% | -5.85 M Increased by +7.85% | Decreased by -2.10 K% Decreased by -54.47% |
| Dec 31, 24 | 278.00 K Decreased by -37.81% | -5.85 M Decreased by -20.89% | Decreased by -2.10 K% Decreased by -94.37% |
| Sep 30, 24 | 5.36 M Increased by +2.42 K% | -366.00 K Increased by +93.59% | Decreased by -6.83% Increased by +99.75% |
| Jun 30, 24 | 5.43 M Increased by +814.65% | 1.98 M Increased by +133.10% | Increased by +36.37% Increased by +103.62% |
| Mar 31, 24 | 466.00 K Decreased by -38.52% | -6.34 M Increased by +79.62% | Decreased by -1.36 K% Increased by +66.85% |
| Dec 31, 23 | 447.00 K Increased by +347.00% | -4.84 M Increased by +2.20% | Decreased by -1.08 K% Increased by +78.12% |
| Sep 30, 23 | 213.00 K Decreased by -18.39% | -5.71 M Decreased by -92.22% | Decreased by -2.68 K% Decreased by -135.54% |
| Jun 30, 23 | 594.00 K Decreased by -83.12% | -5.97 M Decreased by -1.24 K% | Decreased by -1.01 K% Decreased by -6.85 K% |